Duke to start trial of promising COVID treatment

On Sunday, Duke announced that the Duke Human Vaccine Institute (DHVI) was given approval for a clinical trial that, if effective, could advance COVID care until a vaccine can be developed.

The approval means the DHVI can launch Phase 1 of the clinical trial for one of the most promising antibody treatments for COVID-19.

"This would be a temporary treatment until a vaccine is developed," said Duke Today in a statement.

The DHVI is also developing a pan-coronavirus vaccine to combat future iterations of COVID-19 or similar viruses, as well as if saliva could be used as an accurate indicator for COVID-19, according to Duke Today.

This video released by Duke Health Development provides a deeper look into the trials and potential for the antibody treatment.